tuberculosi
tb
infecti
diseas
often
difficult
diagnos
world
health
organis
estim
global
case
detect
rate
tb
suggest
estim
million
incid
case
year
almost
million
case
diagnos
notifi
pulmonari
tb
infecti
form
diseas
diagnos
detect
mycobacterium
tuberculosi
complex
mtbc
bacilli
sampl
sputum
expector
patient
smear
microscopi
primari
test
use
diagnosi
pulmonari
tb
endem
countri
labori
rel
insensit
test
case
detect
rate
microscopi
diagnos
late
stage
tb
diseas
perform
poorli
specimen
acquir
case
hiv
coinfect
due
reduc
number
tb
cell
produc
sputum
specimen
failur
detect
treat
pulmonari
diseas
time
manner
result
onward
transmiss
continu
epidem
claim
estim
million
live
recent
note
approxim
three
million
case
activ
tb
went
undiagnos
countri
program
press
need
improv
diagnost
tool
supplant
smear
microscopi
facilit
rapid
detect
aim
xpert
mtbrif
cepheid
usa
endors
detect
pulmonari
diseas
set
high
incid
tbhiv
coinfect
high
rate
drug
resist
polymeras
chain
reaction
pcr
base
test
fulli
integr
modular
system
detect
tb
infect
indic
presenc
resist
one
key
antituberculosi
drug
rifampicin
key
attribut
genexpert
system
eas
use
major
key
process
integr
autom
dna
extract
interpret
test
result
howev
genexpert
requir
consist
electr
laboratori
temperatur
maintain
pose
logist
challeng
furthermor
cost
cartridg
instrument
mainten
threaten
sustain
longer
term
high
tb
burden
countri
current
reli
global
donor
assist
provid
technolog
therefor
increas
access
time
accur
diagnosi
tb
suspect
patient
rapid
high
perform
tb
diagnost
test
meet
logist
challeng
unsupervis
use
limit
infrastructur
set
requir
price
compar
smear
microscopi
technolog
develop
tb
diagnosi
microscopi
center
high
burden
countri
current
undergo
evalu
includ
semimodular
system
epistem
genedr
molbio
easynat
method
manual
specimen
process
test
determin
eiken
loopamp
tb
ustar
biotechnolog
easi
nat
recent
isotherm
amplif
assay
util
loop
mediat
amplif
lamp
helicas
depend
amplif
hda
cross
prime
amplif
cpa
describ
diagnosi
pulmonari
tb
unlik
pcr
isotherm
assay
requir
precis
control
thermal
cycl
instead
use
uniform
incub
temperatur
typic
permit
dna
amplif
therefor
may
offer
greater
util
simplist
reactor
design
heat
sourc
recombinas
polymeras
amplif
rpa
emerg
novel
isotherm
technolog
use
molecular
diagnosi
infecti
diseas
unlik
mani
isotherm
technolog
rpa
requir
elev
precis
temperatur
may
proceed
temperatur
rpa
replac
thermal
cycl
need
pcr
three
core
enzym
titular
enzym
recombinas
bind
oligonucleotid
primer
form
recombin
filament
recombin
homolog
dna
figur
second
enzym
singlestrand
dna
bind
protein
bind
strand
dna
displac
primer
stabilis
dloop
form
prevent
dissoci
primer
third
core
enzym
stranddisplac
dna
polymeras
copi
dna
templat
ad
base
onto
end
primer
forc
open
dna
doubl
helix
progress
pcr
use
close
space
oppos
primer
allow
exponenti
amplif
defin
region
dna
rpa
reaction
typic
run
complet
minut
depend
amplicon
size
templat
copi
number
time
test
result
significantli
rapid
isotherm
mtbc
assay
note
incub
time
rang
minut
highli
specif
detect
rpa
product
achiev
via
use
custom
design
oligonucleotid
probe
recogn
complementari
region
within
either
strand
rpa
amplicon
probe
dna
also
insert
via
recombinas
mediat
event
rpa
probe
construct
abas
nucleotid
analogu
within
probe
sequenc
abas
site
recognis
cleav
sever
type
endo
exonucleas
probe
bound
complementari
sequenc
differ
nucleas
specif
ad
core
rpa
reaction
mixtur
use
varieti
detect
format
includ
fluoresc
detect
real
time
endpoint
detect
via
later
flow
strip
revers
transcriptas
also
includ
rpa
reaction
facilit
rpa
rna
target
middl
east
respiratori
syndrom
coronaviru
rift
valley
fever
recent
rpa
demonstr
highli
sensit
detect
hiv
provir
dna
work
investig
use
rpa
detect
mycobacterium
tuberculosi
dna
patient
present
suspect
pulmonari
tb
oligonucleotid
primer
probe
use
develop
rpa
assay
purchas
eurogentec
ltd
southampton
uk
biosearch
technolog
novato
ca
respect
preliminari
screen
primer
probe
combin
use
twist
amp
exo
kit
accord
manufactur
instruct
twistdx
ltd
uk
final
reaction
volum
rpa
reaction
incub
use
combin
heat
fluoresc
detect
devic
twista
twistdx
uk
sampl
mix
prior
amplif
also
six
minut
incub
output
rpa
reaction
monitor
real
time
use
twista
studio
softwar
twistdx
uk
fluoresc
measur
taken
everi
second
total
minut
optim
primer
probe
sequenc
identifi
lyophil
pellet
twistamp
exo
reaction
prepar
also
contain
primer
probe
reaction
mm
mgoac
twistamp
primerinpellet
resuspens
buffer
pirb
twistdx
ltd
samplewat
use
rehydr
pellet
doubl
amount
reagent
use
reaction
sampl
incub
condit
remain
use
primer
screen
cultur
tuberculosi
bovi
bcgbulgaria
bbncipd
ltd
bulgaria
maintain
lowenstein
jensen
slant
supplement
glycerol
media
mycobacteria
uk
middlebrook
media
supplement
adc
bd
bbl
usa
dna
extract
use
standardis
rflp
protocol
quantifi
use
qubit
platform
invitrogen
life
technolog
ltd
uk
sampl
purifi
dna
non
tubercul
mycobacteria
ntm
suppli
mycobacteriolog
unit
institut
tropic
medicin
antwerp
belgium
tabl
dna
concentr
quantifi
use
qubit
platform
invitrogen
life
technolog
ltd
uk
pg
genom
sampl
volum
ad
rpa
reaction
use
molecular
weight
per
genom
determin
whole
genom
sequenc
bcg
tokyo
strain
access
calcul
fg
bcg
dna
correl
estim
genom
equival
ge
one
cell
second
panel
fulli
character
ntm
strain
bacteria
includ
common
respiratori
pathogen
access
refer
collect
washington
state
public
health
laboratori
tabl
crude
genom
dna
extract
prepar
describ
previous
evalu
rpa
assay
perform
use
panel
sputum
respiratori
specimen
deriv
suspect
case
pulmonari
tb
obtain
washington
state
public
health
laboratori
sampl
test
rpa
remain
specimen
collect
routin
diagnosi
repres
popul
attend
clinic
select
provid
panel
unusu
high
proport
posit
sampl
studi
investig
blind
statu
sampl
panel
compris
specimen
includ
induc
expector
sputum
n
respiratori
wash
bronchial
tracheal
n
collect
total
tb
suspect
case
two
specimen
per
individu
test
specimen
process
via
digest
decontamin
use
nacetyl
lcystein
naohna
citrat
method
specimen
cell
pellet
centrifug
g
supernat
discard
pellet
resuspend
ml
steril
phosphatebuff
salin
pb
ph
smear
prepar
decontamin
specimen
determin
presenc
acid
fast
bacteria
use
auramin
fluoresc
microscopi
specimen
consid
smear
posit
greater
afb
present
per
observ
microscop
field
smear
posit
specimen
score
scanti
base
number
observ
afb
posit
cell
present
cultur
perform
use
mgit
modifi
middlebrook
liquid
medium
autom
bactec
system
becton
dickinson
compani
new
jersey
usa
incub
month
ml
inoculum
process
specimen
use
per
mycobacteri
cultur
posit
cultur
screen
mtbc
use
mycobacterium
tuberculosi
complex
cultur
identif
test
genprob
san
diego
ca
accord
manufactur
instruct
mtbc
neg
cultur
posit
isol
speciat
addit
biochem
test
aliquot
process
specimen
use
dna
extract
previous
describ
extract
process
use
glass
bead
heat
lysi
use
lyse
sampl
store
use
specimen
screen
rpa
tb
assay
prepar
describ
earlier
rpa
reaction
contain
specimen
extract
ad
rehydr
buffer
mgoac
molecular
grade
water
creat
final
reaction
volum
score
posit
rpa
reaction
incub
twista
rpa
reactor
indic
increas
fam
fluoresc
greater
mv
six
twenti
minut
incub
clinic
materi
use
studi
discard
remain
specimen
collect
routin
diagnost
examin
data
blind
link
enabl
identif
patient
studi
exempt
ethic
approv
accord
us
code
feder
regul
cfr
work
uk
approv
research
ethic
committe
london
school
hygien
tropic
medicin
undertaken
complianc
human
tissu
act
rpa
assay
design
target
insert
sequenc
region
shown
high
sensit
diagnos
tuberculosi
use
pcr
often
present
tuberculosi
multipl
copi
per
genom
convers
mtbc
isol
target
also
describ
mycobacterium
bovi
bacillu
bcg
strain
low
number
copi
bulgarian
bcg
strain
use
studi
two
copi
ensur
coverag
mtbc
speci
second
rpa
assay
insert
sequenc
also
develop
unlik
present
mtbc
speci
stabl
copi
number
repeat
per
genom
bulgarian
bcg
strain
use
studi
six
copi
primer
probe
assay
select
base
upon
sequenc
describ
mtb
whole
genom
ncbi
refer
sequenc
bovi
bcg
initi
design
screen
use
blastn
ncbi
nucleotid
databas
ensur
target
sequenc
primer
probe
exclus
mtbc
speci
differ
rpa
primer
pcr
primer
one
length
base
oligonucleotid
optim
format
effici
recombinas
filament
twistamp
exo
probe
oligonucleotid
typic
base
long
tetrahydrofuran
thf
sometim
refer
dspacer
creat
abas
site
oligonucleotid
probe
sequenc
thf
posit
base
end
base
end
fluorophor
quencher
posit
either
side
thf
moieti
typic
base
apart
commerci
avail
label
phosphoramidit
base
dt
locat
nucleosid
dictat
precis
locat
probe
end
probe
block
prevent
dna
polymeras
extens
undigest
probe
howev
exonucleas
iii
digest
abas
site
within
exo
probe
newli
gener
end
larger
portion
cleav
probe
hydroxyl
group
dna
polymeras
mediat
strand
extens
occur
probe
select
ten
mer
primer
chosen
base
interv
base
overlap
upstream
downstream
target
region
screen
copi
tb
dna
screen
perform
twistamp
exo
reaction
initi
screen
primer
gave
best
amplif
target
dna
redesign
seri
stagger
primer
singl
base
interv
deviat
origin
primer
sequenc
set
screen
effort
identifi
produc
faster
time
result
copi
templat
dna
third
final
round
primer
screen
perform
differ
length
base
vari
end
version
best
primer
figur
show
screen
improv
perform
assay
oligonucleotid
select
amplifi
list
tabl
sensit
rpa
reaction
assess
test
serial
dilut
genom
dna
extract
bovi
bcg
multipl
test
perform
concentr
dna
water
use
neg
control
tabl
exampl
output
shown
figur
time
onset
rise
fluoresc
increas
amount
bcg
genom
dna
sampl
decreas
use
primer
fg
per
reaction
requir
reaction
consist
posit
approxim
equival
dna
found
singl
bacteria
n
shown
figur
test
low
level
dna
time
onset
fluoresc
associ
amount
dna
sampl
min
requir
test
fg
use
primer
consist
posit
result
obtain
sampl
contain
least
fg
bcg
genom
dna
tabl
time
onset
signal
lowest
concentr
fg
rang
minut
result
suggest
either
rpa
assay
highli
sensit
rapid
amplif
detect
mtbc
dna
minut
data
collect
period
suffici
detect
posit
sampl
sensit
also
assess
test
replic
serial
dilut
cultur
bcg
result
shown
indic
rpa
assay
capabl
detect
singl
coloni
form
unit
bacteria
assess
specif
rpa
reaction
identif
mtbc
sampl
dna
panel
non
tubercul
mycobacteria
ntm
test
tabl
posit
control
use
pg
dna
either
bovi
bcg
tuberculosi
use
batch
signal
obtain
bacteri
dna
mtbc
strain
indic
high
specif
primer
use
second
round
screen
challeng
rpa
tb
assay
specif
genom
dna
ntm
nonmycobacteri
speci
use
tabl
crude
dna
extract
deriv
cultur
bacteria
indic
cross
reactiv
rpa
assay
bacteri
speci
confirm
high
specif
assay
across
broad
rang
ntm
diverg
bacteri
speci
specimen
panel
use
assess
rpa
assay
perform
bias
construct
reflect
approxim
mtbc
posit
mtbc
neg
sampl
respect
base
liquid
cultur
result
subsequ
pathogen
identif
fiftysix
specimen
cultur
posit
fortyf
confirm
mtbc
posit
confirm
via
accuprob
test
tabl
remain
eleven
cultur
identifi
ntm
thirtyon
specimen
cultur
neg
three
cultur
contamin
see
tabl
three
new
specimen
acquir
three
later
confirm
mtbc
posit
cultur
accuprob
smear
microscopi
result
panel
observ
afb
rang
scanti
thirtynin
specimen
fiftyon
smear
neg
panel
fortyfour
sampl
found
posit
rpa
tabl
tabl
sensit
specif
rpa
assay
compar
confirm
cultur
ci
ci
respect
indirect
smear
microscopi
less
accur
ci
ci
rpa
assay
detect
smear
posit
tb
sampl
ci
smear
neg
cultur
confirm
tb
specimen
tabl
tabl
four
ntm
found
smear
posit
rpa
neg
panel
use
assess
perform
rpa
assay
also
contain
disproportion
high
number
mtbc
posit
specimen
total
specimen
previous
character
smear
microscopi
cultur
use
due
limit
access
clinic
materi
forti
specimen
use
assay
evalu
also
use
evalu
rpa
assay
remain
isol
screen
rpa
assay
panel
use
contain
cultur
posit
sampl
confirm
mtbc
via
accuprob
ntm
tabl
tabl
remain
sampl
cultur
neg
accord
smear
microscopi
data
panel
contain
smear
posit
specimen
rang
scanti
panel
sampl
found
posit
rpa
tabl
tabl
sensit
specif
rpa
assay
compar
confirm
cultur
ci
respect
indirect
smear
microscopi
less
accur
ci
ci
rpa
detect
smear
posit
tb
sampl
ci
smear
neg
sampl
cultur
confirm
tb
patient
detect
four
ntm
found
smear
posit
rpa
neg
studi
demonstr
applic
rpa
diagnosi
tb
sputum
two
assay
target
separ
repetit
element
examin
demonstr
abil
detect
mtbc
dna
high
degre
sensit
specif
less
minut
two
assay
rpa
consist
detect
fg
genom
dna
thu
could
detect
sampl
estim
contain
genom
equival
singl
bacteri
cell
assay
requir
slightli
higher
amount
dna
fg
expect
reflect
increas
number
copi
insert
element
genom
six
vs
two
suspect
lower
sensit
observ
due
reduc
primer
probe
bind
effici
oligonucleotid
screen
studi
also
rule
possibl
local
secondari
tertiari
dna
structur
affect
recombinas
mediat
insert
oligonucleotid
despit
presenc
high
level
ssdna
bind
protein
rpa
reaction
nonetheless
assay
demonstr
potenti
rpa
diagnost
tool
detect
tuberculosi
sampl
contain
low
number
bacteria
assay
shown
highli
specif
mtbc
challeng
acid
fast
bacteri
speci
caus
tuberculosi
common
commens
respiratori
bacteri
pathogen
perform
rpa
assess
clinic
deriv
specimen
found
assay
high
sensit
isol
smear
cultur
posit
sampl
smear
neg
cultur
posit
identifi
posit
via
assay
respect
note
crude
dna
extract
procedur
use
improv
sampl
handl
dna
extract
may
improv
detect
complex
sampl
matrix
sputum
similarli
wherea
ml
inoculum
use
cultur
volum
taken
dna
extract
ml
use
rpa
assay
may
opportun
improv
sensit
test
larger
sampl
volum
incorpor
sampl
concentr
step
fulfil
full
potenti
rpa
pointofcar
diagnost
integr
platform
perform
sampl
prepar
run
assay
must
develop
work
requir
optim
specif
rpa
tb
diagnosi
clinic
sampl
particular
number
neg
sampl
includ
studi
insuffici
assess
clinic
specif
number
cultureposit
smearneg
sampl
increas
better
determin
clinic
sensit
ten
ten
ntm
posit
specimen
correctli
assign
assay
mtbc
neg
demonstr
specif
howev
wherea
assay
correctli
assign
two
ntm
specimen
neg
two
fals
posit
observ
smear
neg
specimen
cultur
posit
ntm
posit
predict
valu
ppv
neg
predict
valu
npv
present
contriv
composit
mtbc
screen
panel
use
studi
select
demonstr
proof
concept
reflect
normal
distribut
specimen
receiv
routin
screen
pulmonari
mtbc
infect
studi
provid
evid
base
rpa
tool
rapid
sensit
detect
dna
mtbc
compar
low
isotherm
incub
temperatur
combin
rapid
time
result
allow
rpa
use
batteri
power
devic
make
amen
health
clinic
develop
countri
reliabl
electr
suppli
howev
studi
requir
adapt
sampl
extract
methodolog
use
point
care
